Hybio advances GLP-1 pipeline and global reach as profits rise
Tirzepatide filing accepted, first in China Hybio's marketing application for tirzepatide injection was accepted by China's drug regulator, making it the first domestic company to file for this blockbuster diabetes and weight-loss drug. If approved, it opens a huge market and strengthens Hybio's GLP-1 leadership.
This is a major regulatory milestone that could significantly boost future revenue and market position.
Semaglutide partnership expands market reach Hybio signed a cooperation agreement for semaglutide injection in China, covering development, registration, production, and sales. This partnership should accelerate commercialization and broaden patient access, supporting revenue growth.
It directly adds a new commercial channel for a key GLP-1 product, enhancing Hybio's market presence.
Interim profit rises, cash flow strong Hybio reported a net profit of 237 million yuan for the first half of 2026, with operating cash inflow of 305 million yuan. Although gross margin dipped slightly, the profit and cash generation show a healthy core business.
Financial results confirm profitability and cash strength, underpinning investor confidence.
Liraglutide approved in Singapore, global push Hybio's liraglutide injection was approved by Singapore's health authority, marking another step in its international expansion. This follows U.S. approval and supports overseas sales growth, though actual sales timing and scale remain uncertain.
It demonstrates progress in global markets, a key growth driver for the company.